Screening for Colorectal Cancer: A Systematic Review and Meta-Analysis

doi:10.1016/j.clcc.2016.03.003

Clinical Colorectal Cancer

Volume 15, Issue 4, December 2016, Pages 298-313

https://doi.org/10.1016/j.clcc.2016.03.003 Get rights and content

Abstract

To evaluate the effectiveness of colorectal cancer (CRC) screening in asymptomatic adults. A search was conducted of the Medline, Embase, and the Cochrane Library databases. A targeted search of PubMed was conducted for on-topic randomized controlled trials (RCTs). Meta-analysis across 4 RCTs for guaiac fecal occult blood testing (gFOBT) and flexible sigmoidoscopy (FS) screening showed a reduction of 18% (risk ratio [RR], 0.82; 95% CI [CI], 0.73-0.92) and 26% (RR, 0.74; 95% CI, 0.67-0.83) in CRC mortality for the screening group compared to controls, respectively. The number needed to screen (NNS) were 377 (95% CI, 249-887) and 864 (95% CI, 672-1266) for gFOBT and FS screening, respectively. A reduction of 8% and 27% in incidence of late-stage CRC was also observed for gFOBT and FS screening, respectively, but both had no significant effect on all-cause mortality. A single RCT found that screening with immunochemical fecal occult blood test (iFOBT) had no significant impact on CRC mortality (RR, 0.88; 95% CI, 0.72-1.07). Screening with FS has potential harms such as perforation, major and minor bleeding, and death from the procedure or from follow-up colonoscopy. gFOBT and FS screening reduce CRC mortality and incidence of late-stage disease. The absolute effect and NNS were much more favorable for older adults (≥ 60 years), suggesting that a targeted screening approach may avoid exposing younger adults to the harms of CRC screening, from which they are unlikely to derive any significant benefit. Although there is insufficient RCT evidence on the impact of iFOBT on mortality outcomes. compared to gFOBT, this test showed higher sensitivity and comparable specificity, indicating the need to update and reevaluate the evidence in light of future high-quality research. The protocol for this systematic review have been published with PROSPERO 2014: CRD42014009777.

Introduction

In 2012, colorectal cancer (CRC) was the third most common cancer worldwide, resulting in 694,000 deaths.¹ In the United States, CRC is the third most common cancer among men (44.8%) and women (34.1%), as well as the third leading cause of cancer death among both sexes (17.6% and 12.4%, respectively).² In 2012, 134,784 people in the United States were diagnosed with CRC, and 51,516 people died from this disease.²

In 2008, the United States Preventive Services Task Force (USPSTF) recommended that individuals aged 50 to 75 years be screened for CRC using high-sensitivity fecal occult blood testing, sigmoidoscopy, or colonoscopy.³ The systematic review on which this article is based provided evidence for the Canadian Task Force on Preventive Health Care to update their guideline regarding screening for CRC.

Section snippets

Methods

Here we report on selected outcomes that were part of a larger technical report produced for the Canadian Task Force on Preventative Health Care. The protocol was registered with the International Prospective Registry of Systematic Reviews (PROSPERO CRD42014009777). Similar methods have been used and are reported elsewhere by our review team.4, 5, 6

Results

A total of 87 studies met the inclusion criteria for the review; 55 were used to answer our proposed questions (Figure 1). Nine RCTs addressed the benefits of screening, and 46 studies provided data for harms of screening or follow-up testing (Table 1).

Discussion

To our knowledge, this is the most up-to-date and comprehensive review on the benefits and harms of CRC screening in asymptomatic adults. We found a reasonable amount of direct, high-level (RCT), and moderate GRADE-quality evidence for benefits of CRC screening with FOBT and FS. No RCTs were found that provided data regarding the effectiveness of CRC screening using colonoscopy, CT colonography, fecal DNA, barium enema, or digital rectal examination.

Conclusion

CRC screening using FOBT and FS is effective for reducing CRC mortality and incidence of late-stage disease. RCTs evaluating the effects of colonoscopy and CT colonography screening on mortality or incidence of late-stage cancer do not exist. The absolute effect and NNS were much more favorable for an older (≥ 60 years) age group. The relative risk provides little information about actual risk based on age groups. Differences in incidence, underlying baseline risk of dying from CRC, and size of

Acknowledgments

Other McMaster Evidence Review and Synthesis Centre contributors included Sharon Peck-Reid and Maureen Rice. Peer reviewer of the search strategy was Jessie McGowan (associate editor, Journal of Clinical Epidemiology, and adjunct professor, Department of Family Medicine, University of Ottawa).

Clinical expertise was provided by John Marshall (professor of medicine, Division of Gastroenterology, McMaster University). Public Health Agency of Canada staff assistance was provided by Lesley Dunfield

References (67)

R. DerSimonian et al.
Meta-analysis in clinical trials
Control Clin Trials
(1986)
W.S. Atkin et al.
Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial
Lancet
(2010)
D.B. Nelson et al.
Procedural success and complications of large-scale screening colonoscopy
Gastrointest Endosc
(2002)
C. Stock et al.
Adverse events requiring hospitalization within 30 days after outpatient screening and nonscreening colonoscopies
Gastrointest Endosc
(2013)
J.J.Y. Sung et al.
Screening for colorectal cancer in Chinese: comparison of fecal occult blood test, flexible sigmoidoscopy, and colonoscopy
Gastroenterology
(2003)
J. Faivre et al.
Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study
Gastroenterology
(2004)
B. Denis et al.
Harms of colonoscopy in a colorectal cancer screening programme with faecal occult blood test: a population-based cohort study
Dig Liver Dis
(2013)
V. Dancourt et al.
Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms
Eur J Cancer
(2008)
M.J. Denters et al.
Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer
Gasteroenterology
(2012)
J.K. Lee et al.
Cost-effectiveness of a mailed educational reminder to increase colorectal cancer screening
BMC Gastroenterol
(2011)

T.R. Levin et al.

Complications of screening flexible sigmoidoscopy

Gastroenterology

(2002)

D. Lisi et al.

Participation in colorectal cancer screening with FOBT and colonoscopy: an Italian, multicentre, randomized population study

Dig Liver Dis

(2010)

K. Hughes et al.

Guaiac versus immunochemical tests: faecal occult blood test screening for colorectal cancer in a rural community

Aust N Z J Public Health

(2005)

T. Raginel et al.

A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening

Gastroenterology

(2013)

J.K. Lee et al.

Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis

Ann Intern Med

(2014)

World Health Organization. Cancer. Fact sheet 297. February 2015. Available at:...

Centers for Disease Control and Prevention; National Cancer Institute. United States Cancer Statistics 1999-2012 cancer...

M. Pignone et al.

Screening for colorectal cancer in adults at average risk: a summary of the evidence for the US Preventive Services Task Force

Ann Intern Med

(2002)

L. Peirson et al.

Prevention of overweight and obesity in children and youth: a systematic review and meta-analysis

CMAJ Open

(2015)

L. Peirson et al.

Treatment of overweight and obesity in children and youth: a systematic review and meta-analysis

CMAJ Open

(2015)

L. Peirson et al.

Prevention of overweight and obesity in adult populations: a systematic review

CMAJ Open

(2014)

N. Calonge et al.

Screening for colorectal cancer: US Preventive Services Task Force recommendation statement

Ann Intern Med

(2008)

Higgins JPT, Altman DG, Sterne JAC, The Cochrane Statistical Methods Group, The Cochrane Bias Methods Group. Assessing...

J. Brozek et al.

GRADEpro version 3.2 for Windows [Computer program]

(2008)

H.J. Schünemann et al.

Interpreting results and drawing conclusions. Expressing absolute risk reductions

S. Wallis

Binomial confidence intervals and contingency tests: mathematical fundamentals and the evaluation of alternative methods

JQL

(2013)

N. Howlader et al.

SEER Cancer Statistics Review, 1975-2012

(2015)

G.A. Kelley et al.

Statistical models for meta-analysis: a brief tutorial

World J Methodol

(2012)

Identifying and measuring heterogeneity

GRADEpro [Computer program]. Version 2015

(2015)

O. Kronborg et al.

Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds

Scand J Gastroenterol

(2004)

E. Lindholm et al.

Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer

Br J Surg

(2008)

J.H. Scholefield et al.

Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up

Gut

(2012)

Cited by (94)

Perspective; recommendations for improved patient participation in decision-making for geriatric patients in acute surgical settings
2023, Injury
Geriatric patients often present to the hospital in acute surgical settings. In these settings, shared decision-making as equal partners can be challenging. Surgeons should recognize that geriatric patients, and frail patients in particular, may sometimes benefit from de-escalation of care in a palliative setting rather than curative treatment. To provide more person-centred care, better strategies for improved shared decision-making need to be developed and implemented in clinical practice. A shift in thinking from a disease-oriented paradigm to a patient-goal-oriented paradigm is required to provide better person-centred care for older patients. We may greatly improve the collaboration with patients if we move parts of the decision-making process to the pre-acute phase. In the pre-acute phase appointing legal representatives, having goals of care conversations, and advance care planning can help give physicians an idea of what is important to the patient in acute settings.
When making decisions as equal partners is not possible, a greater degree of physician responsibility may be appropriate. Physicians should tailor the “sharedness” of the decision-making process to the needs of the patient and their family.
Behavior of general physicians about lung cancer screening in a French region hosting a pilot study
2023, Respiratory Medicine and Research
Lung cancer is the leading cause of cancer-related death in France and has a 5-year survival rate of 20%. Recent prospective randomized controlled trials revealed that lung cancer-specific mortality decreased in patients who underwent screening using low-dose chest computed tomography (low-dose CT). The DEP KP80 pilot study conducted in 2016 showed that an organized lung cancer screening campaign involving general practitioners was feasible.
We conducted a descriptive observational study of screening practices by sending a self-reported questionnaire to 1013 general practitioners practicing in the Hauts-de-France region.
Our study's primary aim was to investigate the knowledge and practices of general practitioners in the Hauts-de-France region of France regarding lung cancer screening using low-dose CT. The secondary endpoint was to compare practices between general practitioners in the Somme department who had experience of experimental screening and their colleagues in the rest of the region.
The response rate was 18.8% (190 completed questionnaires). Even though 69.5% of the physicians were unaware of the potential benefits of organized low-dose CT screening for lung cancer, 76% proposed screening tests for individual patients. Despite its proven ineffectiveness, chest radiography was still the most widely recommended screening modality. Half of the physicians stated that they had already prescribed chest CT to screen for lung cancer. Additionally, only 36.3% proposed chest CT screening for patients aged over 50 years with a history of more than 30 pack-years. The physicians working in the Somme department (61% had participated in the DEP KP80 pilot study) were more aware of low-dose CT as a screening modality, and offered it significantly more than their colleagues in the other departments (61.1% vs 13.4% p<0.01). All the physicians were in favor of an organized screening program.
More than a third of general practitioners in the Hauts-de-France region offered for lung cancer screening using chest CT, although only 18% specified low-dose CT. Before an organized screening program can be set up, good practice guidelines must be made available about lung cancer screening.
Perceived Importance of the Benefits and Harms of Colorectal Cancer Screening: A Best-Worst Scaling Study
2023, Value in Health
To elicit the relative importance of the benefits and harms of colorectal cancer (CRC) screening among potential screening participants in the Dutch population.
In a consensus meeting with 11 experts, risk reduction of CRC and CRC deaths (benefits) and complications from colonoscopy, stress of receiving positive fecal immunological test (FIT) results, as well as false-positive and false-negative FIT results (harms) were selected as determinant end points to consider during decision making. We conducted an online best-worst scaling survey among adults aged 55 to 75 years from the Dutch Health Care Consumer Panel of The Netherlands Institute for Health Services Research to elicit preference values for these outcomes. The preference values were estimated using conditional logit regression.
Of 265 participants, 234 (89%) had ever participated in CRC screening. Compared with the stress of receiving a positive FIT result, the outcome perceived most important was the risk of CRC death (odds ratio [OR] 4.5; 95% confidence interval [CI] 3.9-5.1), followed by risk of CRC (OR 4.1; 95% CI 3.6-4.7), a false-negative FIT result (OR 3.1; 95% CI 2.7-3.5), colonoscopy complications (OR 1.6; 95% CI 1.4-1.8), and a false-positive FIT result (OR 1.4; 95% CI 1.3-1.6). The magnitude of these differences in perceived importance varied according to age, educational level, ethnic background, and whether the individual had previously participated in CRC screening.
Dutch men and women eligible for FIT-based CRC screening perceive the benefits of screening to be more important than the harms.
Defining the road map to a UK national lung cancer screening programme
2023, The Lancet Oncology
Lung cancer screening with low-dose CT was recommended by the UK National Screening Committee (UKNSC) in September, 2022, on the basis of data from trials showing a reduction in lung cancer mortality. These trials provide sufficient evidence to show clinical efficacy, but further work is needed to prove deliverability in preparation for a national roll-out of the first major targeted screening programme. The UK has been world leading in addressing logistical issues with lung cancer screening through clinical trials, implementation pilots, and the National Health Service (NHS) England Targeted Lung Health Check Programme. In this Policy Review, we describe the consensus reached by a multiprofessional group of experts in lung cancer screening on the key requirements and priorities for effective implementation of a programme. We summarise the output from a round-table meeting of clinicians, behavioural scientists, stakeholder organisations, and representatives from NHS England, the UKNSC, and the four UK nations. This Policy Review will be an important tool in the ongoing expansion and evolution of an already successful programme, and provides a summary of UK expert opinion for consideration by those organising and delivering lung cancer screenings in other countries.
Subsequent participation in organized FIT based screening following screen-derived colonoscopy – A Danish nationwide cohort study
2023, Preventive Medicine Reports
In the Danish National Colorectal Cancer (CRC) screening program, participants with screen-detected low-risk adenomas are invited to a new faecal immunochemical test (FIT) screening after two years. However, participation rate in next FIT screening is unknown. We aimed to investigate this subsequent participation rate within the Danish CRC screening program.
This nationwide register-based study included participants aged 50–72 years registered with FIT screening in the Danish CRC screening program between January 1, 2016, and June 30, 2017. Participants were included if their index FIT was negative or if it was positive and the subsequent colonoscopy detected low-risk adenomas. Invitees were categorized as subsequent participants if they returned a FIT within 135 days following the invitation to screening. We estimated the relative risk for participation depending on screening outcome, age, and sex.
415,107 with a negative result and 5,550 with low-risk adenomas were included. 86.0% (85.9;86.1) of the invitees with a negative result participated in the subsequent screening, while 71.8% (70.6;73.0) of the invitees with low-risk adenomas participated subsequently. The risk of participation in the subsequent screening was significantly lower among all age groups of men and women with low-risk adenomas compared to similar groups with negative results.
Invitees with low-risk adenomas detected at their initial colonoscopy are less likely to participate in the subsequent screening than invitees with negative results. This association was found in all age groups and for both sexes. Further studies are necessary to assess whether non-attendance is more pronounced in specific subgroups.
Outcomes of upper endoscopy screening in Lynch syndrome: a meta-analysis
2023, Gastrointestinal Endoscopy
Lynch syndrome (LS) predisposes affected individuals to a high lifetime risk of malignancies, including colorectal, endometrial, gastric, and duodenal cancers. The role of upper GI (UGI) cancer screening in LS has been uncertain, but recent studies have evaluated its utility.
Databases were queried through December 2021 to identify studies that examined upper endoscopy screening in LS using EGD. Mantel-Haenszel pooled odds ratios and 95% confidence intervals (CIs) for outcomes were constructed using a random-effects model to identify pooled odds of endoscopic findings in persons with LS. Event rates for detection of gastric and duodenal cancers, high-risk lesions, and clinically actionable findings were calculated. Statistical heterogeneity was assessed using the I² statistic.
Nine studies were identified with 2356 LS patients undergoing approximately 7838 EGDs. In total, 47 LS-associated UGI cancers (18 gastric and 29 duodenal cancers), 237 high-risk lesions, and 335 clinically actionable findings were identified. The pooled event rate for detection of any UGI cancer, high-risk lesions, and clinically actionable findings during screening were .9% (95% CI, .3-2.1; I² = 89%), 4.2% (95% CI, 1.6-10.9; I² = 98%), and 6.2% (95% CI, 2.2-16.5; I² = 99%), respectively. There was no difference between LS-associated gene and gastric or duodenal cancer detection.
In LS, there is evidence that endoscopic screening detects UGI cancers, precancerous lesions, and other clinically actionable findings that favor its use as a part of cancer risk management in LS.

View all citing articles on Scopus

View full text

ReviewScreening for Colorectal Cancer: A Systematic Review and Meta-Analysis

Abstract

Introduction

Section snippets

Methods

Results

Discussion

Conclusion

Acknowledgments

Control Clin Trials

Lancet

Gastrointest Endosc

Gastrointest Endosc

Gastroenterology

Gastroenterology

Dig Liver Dis

Eur J Cancer

Gasteroenterology

BMC Gastroenterol

Gastroenterology

Dig Liver Dis

Aust N Z J Public Health

Gastroenterology

Ann Intern Med

Screening for colorectal cancer in adults at average risk: a summary of the evidence for the US Preventive Services Task Force

Ann Intern Med

Prevention of overweight and obesity in children and youth: a systematic review and meta-analysis

CMAJ Open

Treatment of overweight and obesity in children and youth: a systematic review and meta-analysis

CMAJ Open

Prevention of overweight and obesity in adult populations: a systematic review

CMAJ Open

Screening for colorectal cancer: US Preventive Services Task Force recommendation statement

Ann Intern Med

GRADEpro version 3.2 for Windows [Computer program]

Interpreting results and drawing conclusions. Expressing absolute risk reductions

Binomial confidence intervals and contingency tests: mathematical fundamentals and the evaluation of alternative methods

JQL

SEER Cancer Statistics Review, 1975-2012

Statistical models for meta-analysis: a brief tutorial

World J Methodol

Identifying and measuring heterogeneity

GRADEpro [Computer program]. Version 2015

Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds

Scand J Gastroenterol

Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer

Br J Surg

Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up

Gut

Review
Screening for Colorectal Cancer: A Systematic Review and Meta-Analysis